Rep. Laurel Lee Visits Wesley Chapel Cancer Center FORT MYERS, Fla., Aug. 22, 2025 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) Director of Legislative Affairs and Patient Advocacy Richard McDonough, MD last week welcomed U.S. Representative Laurel Lee and her team for a visit to the FCS Wesley Chapel Cancer Center for a firsthand look at the patient experience in the community oncology setting as part of the "Sit in My Chair" program of the Community Oncology Allia

Proprietary model informs targeted sales and marketing strategies with feedback loop that augments precision and impact of targeting and engagement CRANFORD, N.J., Aug. 22, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that it has deployed an

Bio-Thera and STADA agree to extend their biosimilars alliance to cover tocilizumab, a targeted immunomodulatory monoclonal antibody directed against the interleukin-6 receptor, indicated for the treatment of multiple inflammatory and autoimmune disorders Bio-Thera will have responsibility for development, manufacturing, and supply of the biosimilar to Roche's RoActemra ® reference brand STADA will have exclusive rights to commercialize the product in the EU, the UK, Switzerland and selected o

WHITE PLAINS, N.Y. and DALLAS, Aug. 22, 2025 /PRNewswire/ -- Sonic Healthcare USA, Inc. ("SHUSA" or "Sonic") today announced it has acquired substantially all of the assets of Cairo Diagnostics, LLC, Cairo Diagnostics NJ, LLC and Rye Management and Logistics Corp. (collectively referred to as "Cairo"). Cairo is a respected provider of comprehensive hematology oncology diagnostics based in White Plains, New York and with a second laboratory in Woodcliff Lake, New Jersey. With today's closing, SHU

Groundbreaking Clinical Trial to Enroll 300 Patients in Double-Blind, Placebo-Controlled Study of Lysine-Gingipain Inhibitor SAN FRANCISCO, Aug. 22, 2025 /PRNewswire/ -- Lighthouse Pharmaceuticals, a clinical-stage biopharmaceutical company pioneering precision therapies for neurodegenerative diseases, today announced it has been awarded a $49.2 million grant from the National Institute on Aging (NIA), part of the National Institutes of Health (NIH), to support a Phase 2 clinical trial of LHP588

– DAWNZERA demonstrated significant and sustained HAE attack rate reduction and long-term disease control – – Offers longest dosing option for HAE, with dosing every 4 or 8 weeks – – Compelling profile supported by recently published switch data – – Ionis’ second independent launch in just nine months, with potential for two additional launches next year – CARLSBAD, CA, USA I August 21, 2025 I Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (

MELBOURNE, Australia I August 21, 2025 I SMSbiotech, a San Diego–based leader in regenerative medicine, today announced the initiation of its first-in-human Phase 1 clinical trial for Chronic Obstructive Pulmonary Disease (COPD). This milestone marks the transition of years of dedicated research into clinical development, with the goal of delivering a transformative therapy for millions living with this debilitating lung condition. The initiation of our Phase 1 trial for COPD is a profound momen

SANTA MONICA, CA & PHILADELPHIA, PA, USA I August 21, 2025 I Kite, a Gilead Company (Nasdaq: GILD), today announced that it has entered into a definitive agreement to acquire Interius BioTherapeutics, a privately held biotechnology company developing in vivo CAR therapeutics, for $350 million. This acquisition complements Kite’s expertise in cell therapy by incorporating Interius’s integrating in vivo platform. This approach enables the generation of CAR T-cells directly within the patient’s bod

NORTH CHICAGO, IL, USA I August 21, 2025 I AbbVie (NYSE: ABBV ) today announced positive topline results from the second of two pivotal studies of the Phase 3 UP-AA clinical program evaluating the safety and efficacy of upadacitinib (RINVOQ ® ; 15 mg and 30 mg, once daily) in adult and adolescent patients with severe alopecia areata (AA) with a mean baseline SALT score of 84.0 (approximately 16% scalp hair coverage). 1 In Study 1, both doses of upadacitinib achieved the primary endpoint, with 45

REYKJAVIK, Iceland and LONDON, UK I August 21, 2025 I Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Commission has approved Mynzepli ® as a biosimilar to Eylea ® (aflibercept), in a